In this prospective phase 2 study, we investigated the efficacy and safety of sintilimab plus anlotinib without chemotherapy in pretreated patients with advanced NSCLC harboring uncommon EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.